glp-1 agonist and grapefruit GLP1 Receptor Agonists—Effects beyond Obesity Diabetes 🧠Let's break the drug tirzepatide

Activation of autophagy is regarded as a promising strategy for the prevention and treatment of metabolic diseases 65

It produces more modest results than semaglutide or tirzepatide, typically around 8 percent body weight loss, but it was the first GLP-1 to receive FDA approval specifically for weight management and remains a viable option for patients who prefer a shorter-acting medication or who experience intolerable side effects on the more potent formulations

In February 2025, the FDA announced that the shortage of semaglutide injectable products (Ozempic, Wegovy) has been resolved, Dulaglutide (Trulicity) shortage resolved in June 2025

Unlike phentermine, every major GLP-1 medication carries FDA approval for long-term use

Some practitioners start with semaglutide (more data) and switch to tirzepatide (broader mechanism) if response is insufficient

11 However, a dose-specific analysis revealed that the beneficial effect of efpeglenatide on HF hospitalisation was primarily seen in the 6 mg group, in which there was a 50% RRR in HF hospitalisation (HR 0.50)